Ash A. Alizadeh, MD/PhD

5.0/5

21 Patient Ratings

87 Patient Reviews

Ash A. Alizadeh, MD/PhD

Medical oncologist, Lymphoma specialist, Cancer geneticist

Moghadam Family Professor

View Professional Summary

Additional Languages Spoken:

Farsi , Persian

Insurance Coverage

Online Second Opinion Program

Resources for Referring Physicians

Biography

Ash A Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, and leader of the Cancer Genomics Program at Stanford Cancer Institute. His primary research interests are in the development and application of genome technologies and computing (machine learning & data science) to a range of problems in human disease, with special focus on cancer detection, classification, monitoring, and tumor immunology. As a longstanding member of NIH Cancer Genetics (CG) Study Section, he helps the Center for Scientific Review with genome scale studies focused on cancer pathogenesis.

Dr. Alizadeh leads a group interested in techniques and methods for understanding tumor behavior at molecular, cellular, organism and population levels. In this effort, his group studies cancer genomic profiles obtained either from tumor tissues, or from noninvasive “liquid biopsies”. Using machine learning techniques, his lab studies how cellular compositional variation impacts cancer behavior and therapeutic response (e.g., http://cibersortx.stanford.edu, http://precog.stanford.edu, and http://ecotyper.stanford.edu), including anti-tumor immunity (http://maria.stanford.edu).

Dr. Alizadeh's group has helped pioneer a range of noninvasive cancer genomic techniques that enable “liquid biopsies”, including CAPP-Seq (https://cappseq.stanford.edu), PhasED-Seq (https://phasedseq.stanford.edu), and EPIC-Seq (https://epicseq.stanford.edu). Using such techniques work from his group focuses on the analysis of circulating nucleic acids to address problems for early cancer detection (http://clip.stanford.edu) and noninvasive cancer monitoring, including prediction of therapeutic response (http://ciri.stanford.edu & http://direct.stanford.edu).

Dr. Alizadeh holds a BS in Biochemistry from UCLA, an MD from Stanford Medical School, a PhD in Biophysics from Stanford, with additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). He has received a number of key awards for his work, including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, Doris Duke Charitable Research Foundation, among others. He is an elected member of the American Society for Clinical Investigation (ASCI), and an elected member of the Scientific Advisory Board (SAB) of the Lymphoma Research Foundation (LRF).

Dr. Alizadeh is a past-President of the American Society of Hematology (ASH) Meeting on Lymphoma Biology, a founding member of the International Lymphoma ctDNA Consortium & Working Group, and past-Chair of the Scientific Committee on Genetics & Epigenetics for the American Society of Hematology (ASH), and past-Chair the Scientific Committee on Lymphoma & Myeloma for the American Society of Clinical Oncology (ASCO). Dr. Alizadeh is a co-founder of CAPP Medical, CiberMED, and Foresight Diagnostics. Dr. Alizadeh is board certified in Medical Oncology, Hematology, and Internal Medicine, a member of the Stanford Lymphoma Program, and received the Stanford Department of Medicine Research Award in 2005. He is a member of the Scientific Advisory Board for Cell, and Scientific Editor for Blood, Cancer Discovery, Blood Cancer Discovery, and the Journal of Clinical Oncology (JCO) and Precision Oncology (PO).

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Medical Oncology (2021)
Medical Education: Stanford University School of Medicine (2003) CA
Fellowship: Stanford University Hematology and Oncology Fellowship (2009) CA
- Residency: Stanford University Internal Medicine Residency (2006) CA
- MD, Stanford university School of Medicine, Medicine (2003)
- PhD, Stanford university School of Medicine, Biophysics/Dept of Biochemistry (2003)
- B.S., UCLA, Biochemistry (1994)

View More Education & Certifications

Honors & Awards

American Society for Clinical Oncology Career Development Award, Stanford University (2010-2013)
American Society of Hematology Scholar Award, Stanford University (2015-2017)
Bent & Janet Cardan Oncology Research Fellow, Stanford University (2010)
- Cancer Innovation Award, Stanford Hospital & Clinics (2012-2013)
- Celgene Young Investigator Award, Stanford University (2014-2015)
- Clinical Investigator Program: Fellow Award, Stanford University Medical Center (2004-2010)
- Damon Runyon Cancer Research Foundation Clinical Investigator Award, Stanford University (2014-2017)
- Doris Duke Clinical Scientist Development Award, Stanford University (2011)
- Franklin G. Ebaugh, Jr. Award for Outstanding Research, Dept of Medicine, Stanford (2004-2005)
- Garbrielle's Angel Foundation, Stanford University (2012-2015)
- Intramural Research Award, NIH/NCI (1997 - 1998)
- Josephine Q. Berry Faculty Scholar in Cancer Research, Stanford University (2010)
- Leukemia & Lymphoma Society Special Fellow in Clinical Research, Stanford University (2010-2013)
- Magna cum laude, College & Departmental Honors, UCLA (6/1993)
- Medical Scientist Training Program Award, NIH (1996-2003)
- NIH Research Fellow Award, NIH/NCI (6/1995)
- Research Scholar Award, HHMI-NIH (1996 - 1998)
- Research Scholar Award for Outstanding Research, HHMI (1998)
- Sandler Fellow Award, UCSF (2003-2004)
- V-Foundation Scholar/Martin D Abeloff Award (1st Place), Stanford University (2014-2016)

View More Honors & Awards

Memberships

Vice Chair, Committee on Epigenetics and Genomics, American Society of Hematology (2014 - Present)
Mentor, Lymphoma Clinical Research Mentoring Program, Lymphoma Research Foundation (2013 - Present)
Leader, Scientific Program Committee on Lymphoma, Myeloma, Plasma Cell Disorders, American Society of Clinical Oncology (2011 - 2014)

Administrative Appointments

Admissions Panel, Medical Scientist Training Program, Stanford University (2011 - Present)
Admissions Panel, Stanford Medical School (2012 - Present)
Chair, Seminar Committee, Stanford Immunology Program (2011 - Present)
- Steering Committee Member & Mentor, Stanford Computational & Systems Immunology (2012 - Present)

View More Administrative Appointments

Publications

Genome-wide analysis of DNA copy-number changes using cDNA microarrays
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., … Brown, P. O. (1999). Genome-wide analysis of DNA copy-number changes using cDNA microarrays. NATURE GENETICS, 23(1), 41–46.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., … Staudt, L. M. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. NATURE, 403(6769), 503–11.
Genomic-scale gene expression profiling of normal and malignant immune cells
Alizadeh, A. A., & Staudt, L. M. (2000). Genomic-scale gene expression profiling of normal and malignant immune cells. CURRENT OPINION IN IMMUNOLOGY, 12(2), 219–25.
- Examining the living genome in health and disease with DNA microarrays
  Diehn, M., Alizadeh, A. A., & Brown, P. O. (2000). Examining the living genome in health and disease with DNA microarrays. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 283(17), 2298–99.
- Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas
  Lossos, I. S., Alizadeh, A. A., Eisen, M. B., Chan, W. C., Brown, P. O., Botstein, D., … Levy, R. (2000). Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(18), 10209–13.
- 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.
  Hastie, T., Tibshirani, R., Eisen, M. B., Alizadeh, A., Levy, R., Staudt, L., … BROWN, P. (2000). 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biology, 1(2), RESEARCH0003-?
- Supervised harvesting of expression trees
  Hastie, T., Tibshirani, R., Botstein, D., & Brown, P. (2001). Supervised harvesting of expression trees. GENOME BIOLOGY, 2(1).
- The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes
  Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., … Staudt, L. M. (1999). The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Presented at the 64th Symposia: Signaling and Gene Expression in the Immune System, NEW YORK,NY,NY,NY: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.
- Genomic analysis of renal allograft dysfunction using cDNA microarrays
  Sarwal, M., Chang, S., Barry, C., Chen, X., Alizadeh, A., Salvatierra, O., & BROWN, P. (2001). Genomic analysis of renal allograft dysfunction using cDNA microarrays. TRANSPLANTATION PROCEEDINGS, 33(1-2), 297–98.
- Towards a novel classification of human malignancies based on gene expression patterns
  Alizadeh, A. A., Ross, D. T., Perou, C. M., & van de Rijn, M. (2001). Towards a novel classification of human malignancies based on gene expression patterns. JOURNAL OF PATHOLOGY, 195(1), 41–52.
- Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
  Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., … Staudt, L. M. (2001). Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. JOURNAL OF EXPERIMENTAL MEDICINE, 194(11), 1639–47.
- Stereotyped and specific gene expression programs in human innate immune responses to bacteria
  Boldrick, J. C., Alizadeh, A. A., Diehn, M., Dudoit, S., Liu, C. L., Belcher, C. E., … Relman, D. A. (2002). Stereotyped and specific gene expression programs in human innate immune responses to bacteria. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(2), 972–77.
- In vivo regulation of human skeletal muscle gene expression by thyroid hormone
  Clement, K., Viguerie, N., Diehn, M., Alizadeh, A., Barbe, P., Thalamas, C., … Langin, D. (2002). In vivo regulation of human skeletal muscle gene expression by thyroid hormone. GENOME RESEARCH, 12(2), 281–91.
- The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile
  Huang, J. Z., Sanger, W. G., Greiner, T. C., Staudt, L. M., Weisenburger, D. D., Pickering, D. L., … Chan, W. C. (2002). The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. BLOOD, 99(7), 2285–90.
- Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes
  Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., … Levy, R. (2002). Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(13), 8886–91.
- Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation
  Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., … Brown, P. O. (2002). Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(18), 11796–801.
- Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations
  Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., … Lossos, I. S. (2003). Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. BLOOD, 101(8), 3109–17.
- Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays
  Liu, C. L., Prapong, W., Natkunam, Y., Alizadeh, A., Montgomery, K., Gilks, C. B., & van de Rijn, M. (2002). Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. AMERICAN JOURNAL OF PATHOLOGY, 161(5), 1557–65.
- HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma
  Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., & Levy, R. (2003). HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. BLOOD, 101(2), 433–40.
- SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
  Diehn, M., Sherlock, G., Binkley, G., Jin, H., Matese, J. C., Hernandez-Boussard, T., … Alizadeh, A. A. (2003). SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. NUCLEIC ACIDS RESEARCH, 31(1), 219–23.
- Individuality and variation in gene expression patterns in human blood
  Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., & Brown, P. O. (2003). Individuality and variation in gene expression patterns in human blood. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(4), 1896–1901.
- Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues
  Kraan, T. C. T. M. V., van Gaalen, F. A., Kasperkovitz, P. V., Verbeet, N. L., Smeets, T. J. M., Kraan, M. C., … Verweij, C. L. (2003). Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. ARTHRITIS AND RHEUMATISM, 48(8), 2132–45.
- T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression.
  Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., … Weiss, A. (2003). T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biology, 1(2), E53-?
- Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.
  Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., … Brown, P. O. (2004). Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biology, 2(2), E7-?
- Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
  Pathan, N., Hemingway, C. A., Alizadeh, A. A., Stephens, A. C., Boldrick, J. C., Oragui, E. E., … Levin, M. (2004). Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. LANCET, 363(9404), 203–9.
- Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
  Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., & Levy, R. (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. NEW ENGLAND JOURNAL OF MEDICINE, 350(18), 1828–37.
- Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
  Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A., Arthur, D. C., … Staudt, L. M. (2004). Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. BLOOD, 104(5), 1428–34.
- AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity
  Lossos, I. S., Levy, R., & Alizadeh, A. A. (2004). AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. LEUKEMIA, 18(11), 1775–79.
- Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas
  Lu, X. Q., Nechushtan, H., Ding, F. Y., Rosado, M. F., Singal, R., Alizadeh, A. A., & Lossos, I. S. (2005). Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. BLOOD, 105(7), 2924–2932.
- Cell-type specific gene expression profiles of leukocytes in human peripheral blood
  Palmer, C., Diehn, M., Alizadeh, A. A., & Brown, P. O. (2006). Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC GENOMICS, 7.
- Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray
  Chiu, C. Y., Alizadeh, A. A., Rouskin, S., Merker, J. D., Yeh, E., Yagi, S., … DeRisi, J. L. (2007). Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray. JOURNAL OF CLINICAL MICROBIOLOGY, 45(7), 2340–43.
- Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center
  Alizadeh, A. A., & Lossos, I. S. (2008). Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center. LEUKEMIA & LYMPHOMA, 49(3), 377–80.
- Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
  Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical Advances in Hematology & Oncology : H&O, 6(12), 899–909.
- Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
  Alizadeh, A. A., Gentles, A. J., Lossos, I. S., & Levy, R. (2009). Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 360(26), 2794–95.
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
  Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., … Weissman, I. L. (2009). CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. CELL, 138(2), 286–99.
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion
  Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., … Levy, R. (2009). Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion. BLOOD, 114(16), 3431–38.
- Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
  Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., … Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594–97.
- Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha
  Alizadeh, A. A., Bohen, S. P., Lossos, C., Martinez-Climent, J. A., Ramos, J. C., Cubedo-Gil, E., … Lossos, I. S. (2010). Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. LEUKEMIA & LYMPHOMA, 51(7), 1200–1216.
- B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
  Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., … Levy, R. (2010). B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(29), 12747–54.
- Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81.
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
  Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., … Majeti, R. (2011). Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. CANCER RESEARCH, 71(4), 1374–84.
- Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
  Gentles, A. J., Plevritis, S. K., Majeti, R., & Alizadeh, A. A. (2010). Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304(24), 2706–15.
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
  Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., … Weissman, I. L. (2010). Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. SCIENCE TRANSLATIONAL MEDICINE, 2(63).
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
  Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., … Levy, R. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. BLOOD, 117(8), 2423–32.
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
  Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011). Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(12), 5009–14.
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
  Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–58.
- Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia
  Alizadeh, A. A., & Majeti, R. (2011). Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia. CANCER CELL, 20(2), 135–36.
- Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
  Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2011). Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. HEMATOLOGICAL ONCOLOGY, 29(3), 157–60.
- Utility of positron emission tomography scans in mantle cell lymphoma
  Hosein, P. J., Pastorini, V. H., Paes, F. M., Eber, D., Chapman, J. R., Serafini, A. N., … Lossos, I. S. (2011). Utility of positron emission tomography scans in mantle cell lymphoma. AMERICAN JOURNAL OF HEMATOLOGY, 86(10), 841–45.
- Treatment advances have not improved the early death rate in acute promyelocytic leukemia
  McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36.
- A proteomic approach for the identification of novel lysine methyltransferase substrates
  Levy, D., Liu, C. L., Yang, Z., Newman, A. M., Alizadeh, A. A., Utz, P. J., & Gozani, O. (2011). A proteomic approach for the identification of novel lysine methyltransferase substrates. EPIGENETICS & CHROMATIN, 4.
- A few good genes Simple, biologically motivated signatures for cancer prognosis
  Gentles, A. J., & Alizadeh, A. A. (2011). A few good genes Simple, biologically motivated signatures for cancer prognosis. CELL CYCLE, 10(21), 3615–16.
- A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma
  Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., & Lossos, I. S. (2012). A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. LEUKEMIA & LYMPHOMA, 53(7), 1299–1305.
- First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma
  Powel, M. S., Alizadeh, A. A., Budvytiene, I., Schaenman, J. M., & Banaei, N. (2012). First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma. JOURNAL OF CLINICAL MICROBIOLOGY, 50(3), 1125–27.
- Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies
  Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., … Utz, P. J. (2012). Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. ARTHRITIS RESEARCH & THERAPY, 14(1).
- Three differentiation states risk-stratify bladder cancer into distinct subtypes
  Volkmer, J.-P., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., … Chan, K. S. (2012). Three differentiation states risk-stratify bladder cancer into distinct subtypes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(6), 2078–83.
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
  Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., … Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6662–67.
- Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
  Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60.
- The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses
  Pachynski, R. K., Zabel, B. A., Kohrt, H. E., Tejeda, N. M., Monnier, J., Swanson, C. D., … Butcher, E. C. (2012). The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. JOURNAL OF EXPERIMENTAL MEDICINE, 209(8), 1427–35.
- Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.
  Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., … Utz, P. J. (2012). Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Research & Therapy, 14(4), 403-?
- CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications
  Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., … Natkunam, Y. (2012). CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications. AMERICAN JOURNAL OF PATHOLOGY, 181(3), 795–803.
- Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
  Keegan, T. H. M., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., … Glaser, S. L. (2013). Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. Leukemia & Lymphoma, 54(4), 743–751.
- Self-antigen recognition by follicular lymphoma B-cell receptors
  Sachen, K. L., Strohman, M. J., Singletary, J., Alizadeh, A. A., Kattah, N. H., Lossos, C., … Levy, R. (2012). Self-antigen recognition by follicular lymphoma B-cell receptors. BLOOD, 120(20), 4182–90.
- Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma
  Huse, K., Bakkebo, M., Walchli, S., Oksvold, M. P., Hilden, V. I., Forfang, L., … Myklebust, J. H. (2012). Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma. PLOS ONE, 7(10).
- Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.
  Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., … Alizadeh, A. A. (2013). Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 121(9), 1604–11.
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
  Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., … Levy, R. (2013). High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood, 121(8), 1367–76.
- Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.
  Romero-Camarero, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Dueñas, C., Gonzalez-Herrero, I., … Lossos, I. S. (2013). Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature Communications, 4, 1338-?
- Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma.
  Gentles, A. J., & Alizadeh, A. A. (2013). Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma. Blood, 121(15), 3052–54.
- Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.
  Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Tibshirani, R. J., … Lowsky, R. (2013). Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clinical Immunology , 148(1), 124–35.
- Probing lymphocyte biology by genomic-scale gene expression analysis
  Alizadeh, A., Eisen, M., Botstein, D., Brown, P. O., & Staudt, L. M. (1998). Probing lymphocyte biology by genomic-scale gene expression analysis. JOURNAL OF CLINICAL IMMUNOLOGY, 18(6), 373–79.
- Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling
  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. (2003). N Engl J Med, 349(2).
- Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma
  Chao, M. P., & Majeti R. (2010). Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma. Cell, 142(5).
- Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS)
  Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). (2010). Blood (e-Letter), 113(1).
- A pluripotency signature predicts histological transformation and influences survival in follicular lymphoma patients
  A pluripotency signature predicts histological transformation and influences survival in follicular lymphoma patients. (2009). Blood.
- Exploring gene expression signatures of host responses to infection
  Boldrick, J. C., Belcher, C. E., Alizadeh, A. A., Liu, C. L., Diehn, M., Brown, P. O., & Relman, D. A. (2000). Exploring gene expression signatures of host responses to infection. CLINICAL INFECTIOUS DISEASES, 31(1), 218–18.
- Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.
  Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., & Levy, R. (2009). Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma. BLOOD, 114(22), 1153–53.
- Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
  Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., … Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836–37.
- Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival
  Newman, A. M., Gentles, A. J., Plevritis, S. K., & Alizadeh, A. A. (2012). Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival. BLOOD, 120(21).
- CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
  Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., & Weissman, I. L. (2008). CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. BLOOD, 112(11), 284–84.
- CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB
  Chao, M. P., Alizadeh, A., Tang, C. Z., Jan, M., Levy, R., Majeti, R., & Weissman, I. L. (2009). CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB. EXPERIMENTAL HEMATOLOGY, 37(9), S8–S9.
- Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts
  Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Jan, M., … Majeti, R. (2009). Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. BLOOD, 114(22), 1063–64.
- LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study.
  Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., … Natkunam, Y. (2008). LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. BLOOD, 112(11), 1291–91.
- Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions
  Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., … Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258–58.
- Therapeutic Potential of Anti-CD137 Antibody in Lymphoma
  Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., … Levy, R. (2009). Therapeutic Potential of Anti-CD137 Antibody in Lymphoma. BLOOD, 114(22), 301–2.
- A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling
  Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K., Alizadeh, A. A., … Levy, R. (2009). A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling. BLOOD, 114(22), 316–16.
- NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome
  Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, D., Houot, R., … Levy, R. (2010). NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome. BLOOD, 116(21), 67–68.
- Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies
  Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., … Levy, R. (2010). Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. BLOOD, 116(21), 1291–92.
- Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma
  Layn, K., Alizadeh, A. A., Kattah, N., Levy, S., & Levy, R. (2010). Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma. BLOOD, 116(21), 1678–79.
- Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results
  Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., … Levy, R. (2011). Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. BLOOD, 118(21), 1323–23.
- Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma
  Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., & Alizadeh, A. A. (2012). Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma. BLOOD, 120(21).
- Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy
  Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Alizadeh, A. A., & Levy, R. (2012). Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. BLOOD, 120(21).
- Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds
  Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., … Brown, P. O. (2004). Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLOS BIOLOGY, 2(2), 206–14.
- Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling.
  Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., … Sarwal, M. (2010). Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. Presented at the 10th American Transplant Congress, SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: WILEY-BLACKWELL.
- T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression
  Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., … Weiss, A. (2003). T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLOS BIOLOGY, 1(2), 271–87.
- The chemoattractant chemerin as a natural tumor suppressive cytokine.
  Pachynski, R. K., Zabel, B., Tejeda, N., Monnier, J., Holzer, A. K., Gentles, A., … Butcher, E. (2012). The chemoattractant chemerin as a natural tumor suppressive cytokine. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
  Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–21.
- Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
  Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., … Lowsky, R. (2012). Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. BLOOD, 120(21).
- Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling
  Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., Sarwal, M., & Lowsky, R. (2010). Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. BLOOD, 116(21), 393–94.
- Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies (vol 14, R25, 2012)
  Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., … Utz, P. J. (2012). Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies (vol 14, R25, 2012). ARTHRITIS RESEARCH & THERAPY, 14(4).
- Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study
  Liu, C. L., Dai, B., Newman, A. M., Majeti, R., & Alizadeh, A. A. (2012). Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study. BLOOD, 120(21).
- Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer
  Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., … Diehn, M. (2012). Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S713–S713.
- The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL
  Coutinho, R., Newman, A. M., Rossignoli, G., Day, W., Miraki-Moud, F., Chaplin, T., … Gribben, J. G. (2012). The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. BLOOD, 120(21).
- Gene expression in large B-cell lymphoma using cDNA microarray technology.
  Chan, W. C., Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., … Staudt, L. M. (1999). Gene expression in large B-cell lymphoma using cDNA microarray technology. BLOOD, 94(10), 698A–698A.
- Three differentiation states risk-stratify bladder cancer into distinct subtypes (vol 109, pg 2078, 2012)
  Volkmer, J.-P., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., … Chan, K. S. (2012). Three differentiation states risk-stratify bladder cancer into distinct subtypes (vol 109, pg 2078, 2012). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(9), 3600–3600.
- Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–47.
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
  Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548–54.
- Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
  Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., … Sánchez-García, I. (2014). Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 5, 3904-?
- Common progenitor cells in mature B-cell malignancies: implications for therapy.
  Green, M. R., & Alizadeh, A. A. (2014). Common progenitor cells in mature B-cell malignancies: implications for therapy. Current Opinion in Hematology, 21(4), 333–40.
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
  Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552–58.
- Tumor antigen discovery through translation of the cancer genome.
  Khodadoust, M. S., & Alizadeh, A. A. (2014). Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 58(2-3), 292–99.
- Hit-and-run lymphomagenesis by the Bcl6 oncogene.
  Green, M. R., Vicente-Dueñas, C., Alizadeh, A. A., & Sánchez-García, I. (2014). Hit-and-run lymphomagenesis by the Bcl6 oncogene. Cell Cycle , 13(12), 1831–32.
- Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
  Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., … Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology , 32(17), 1797–1803.
- Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma
  Green, M. R., Vicente-Duenas, C., Romero-Camarero, I., Liu, C. L., Dai, B., Gonzalez-Herrero, I., … Sanchez-Garcia, I. (2014). Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. NATURE COMMUNICATIONS, 5.
- Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study
  Keegan, T. H. M., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., … Glaser, S. L. (2013). Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. LEUKEMIA & LYMPHOMA, 54(4), 743–51.
- Common progenitor cells in mature B-cell malignancies: implications for therapy
  Green, M. R., & Alizadeh, A. A. (2014). Common progenitor cells in mature B-cell malignancies: implications for therapy. CURRENT OPINION IN HEMATOLOGY, 21(4), 333–40.
- Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation
  Romero-Camarero, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., … Lossos, I. S. (2013). Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. NATURE COMMUNICATIONS, 4.
- Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
  Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., … Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology , 32(17), 1797–1803.
- A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates
  Tian, L., Alizadeh, A. A., Gentles, A. J., & Tibshirani, R. (2014). A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 109(508), 1517–32.
- FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
  Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., & Alizadeh, A. A. (2014). FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. BIOINFORMATICS, 30(23), 3390–93.
- Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
  Bratman, S. V., Newman, A. M., Alizadeh, A. A., & Diehn, M. (2015). Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 1–5.
- Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
  Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., … Alizadeh, A. A. (2015). Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 112(10), E1116–25.
- Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
  Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–87.
- Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., & Arber, D. A. (2014). Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 142(6), 803–8.
- A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.
  Tian, L., Alizadeh, A. A., Gentles, A. J., & Tibshirani, R. (2014). A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates. Journal of the American Statistical Association, 109(508), 1517–1532.
- Robust enumeration of cell subsets from tissue expression profiles.
  Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., … Alizadeh, A. A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nature Methods, 12(5), 453–57.
- Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.
  Whiting, C. C., Siebert, J., Newman, A. M., Du, H.-W., Alizadeh, A. A., Goronzy, J., … Maecker, H. T. (2015). Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PloS One, 10(7).
- The prognostic landscape of genes and infiltrating immune cells across human cancers
  Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., … Alizadeh, A. A. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. NATURE MEDICINE, 21(8), 938–45.
- Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
  Gentles, A. J., Bratman, S. V., Lee, L. J., Harris, J. P., Feng, W., Nair, R. V., … Diehn, M. (2015). Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 107(10).
- Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging
  Whiting, C. C., Siebert, J., Newman, A. M., Du, H.-W., Alizadeh, A. A., Goronzy, J., … Maecker, H. T. (2015). Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLOS ONE, 10(7).
- Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
  Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., … Alizadeh, A. A. (2015). Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 112(10), E1116–25.
- Organocatalytic removal of formaldehyde adducts from RNA and DNA bases
  Karmakar, S., Harcourt, E. M., Hewings, D. S., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., … Kool, E. T. (2015). Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. NATURE CHEMISTRY, 7(9), 752–58.
- Robust enumeration of cell subsets from tissue expression profiles
  Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., … Alizadeh, A. A. (2015). Robust enumeration of cell subsets from tissue expression profiles. NATURE METHODS, 12(5), 453-?
- Organocatalytic removal of formaldehyde adducts from RNA and DNA bases.
  Karmakar, S., Harcourt, E. M., Hewings, D. S., Scherer, F., Lovejoy, A. F., Kurtz, D. M., … Kool, E. T. (2015). Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. Nature Chemistry, 7(9), 752–58.
- Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
  Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., & Diehn, M. (2015). Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in Radiation Oncology, 25(4), 305–12.
- Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
  Gentles, A. J., Bratman, S. V., Lee, L. J., Harris, J. P., Feng, W., Nair, R. V., … Diehn, M. (2015). Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 107(10).
- Integrated digital error suppression for improved detection of circulating tumor DNA
  Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547–55.
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
  Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. NATURE COMMUNICATIONS, 7.
- High-throughput genomic profiling of tumor-infiltrating leukocytes.
  Newman, A. M., & Alizadeh, A. A. (2016). High-throughput genomic profiling of tumor-infiltrating leukocytes. Current Opinion in Immunology, 41, 77–84.
- Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
  Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., … Diehn, M. (2016). Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery.
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364).
- Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
  Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., … Alizadeh, A. A. (2017). Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. NATURE, 543(7647), 723-?
- Toward understanding and exploiting tumor heterogeneity
  Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., … Zucman-Rossi, J. (2015). Toward understanding and exploiting tumor heterogeneity. NATURE MEDICINE, 21(8), 846–53.
- Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
  Myklebust, J. H., Brody, J., Kohrt, H. E., Kolstad, A., Czerwinski, D. K., Wälchli, S., … Levy, R. (2017). Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood, 129(6), 759–70.
- Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
  Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., … Diehn, M. (2017). Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. CANCER DISCOVERY, 7(1), 86–101.
- Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice
  Garcia-Ramirez, I., Tadros, S., Gonzalez-Herrero, I., Martin-Lorenzo, A., Rodriguez-Hernandez, G., Moore, D., … Green, M. R. (2017). Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. BLOOD, 129(19), 2645–56.
- overexpression to promote lymphoma in mice.
  García-Ramírez, I., Tadros, S., González-Herrero, I., Martín-Lorenzo, A., Rodríguez-Hernández, G., Moore, D., … Green, M. R. (2017). overexpression to promote lymphoma in mice. Blood, 129(19), 2645–56.
- Data normalization considerations for digital tumor dissection.
  Newman, A. M., Gentles, A. J., Liu, C. L., Diehn, M., & Alizadeh, A. A. (2017). Data normalization considerations for digital tumor dissection. Genome Biology, 18(1), 128.
- Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma
  Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., … Alizadeh, A. A. (2016). Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. BLOOD. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.
- Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery.
- Profiling Tumor Infiltrating Immune Cells with CIBERSORT.
  Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. (2018). Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology (Clifton, N.J.), 1711, 243–59.
- Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., … van de Rijn, M. (2018). Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Genomic feature selection by coverage design optimization
  Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., & Tibshirani, R. (2018). Genomic feature selection by coverage design optimization. Journal of Applied Statistics.
- NONINVASIVE PREDICTION OF GRAFT-VERUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BY GENE EXPRESSION PROFILING
  Kohrt, H. E., Li, L., Alizadeh, A. A., Heish, S., Goldstein, M. J., Strober, S., … Lowsky, R. (2011). NONINVASIVE PREDICTION OF GRAFT-VERUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BY GENE EXPRESSION PROFILING. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(2), S336.
- Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., … Diehn, M. (2017). Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Analysis of Circulating Tumor DNA in Esophageal Carcinoma Patients Treated With Chemoradiation Therapy
  Klass, D., Newman, A., Lovejoy, A. F., Zhou, L., Stehr, H., Xu, T., … Diehn, M. (2015). Analysis of Circulating Tumor DNA in Esophageal Carcinoma Patients Treated With Chemoradiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3), S104–S105.
- Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing
  Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., … Alizadeh, A. (2014). Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
  Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., … Diehn, M. (2017). Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC
  Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. C. W., Neal, J. W., Wakelee, H. A., … Diehn, M. (2014). Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
  Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA as a Biomarker for Pancreatic Adenocarcinoma
  Osmundson, E., Newman, A. M., Bratman, S. V., Klass, D. M., Zhou, L., Pai, J., … Diehn, M. (2014). Circulating Tumor DNA as a Biomarker for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S816–S817.
- Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
  Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2017). Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC
  Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., … Telli, M. L. (2015). Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
  Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., … Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Pretreatment Circulating Tumor DNA for Risk Stratification of Locally Advanced Esophageal Cancer Treated With Chemoradiation and Surgery
  Azad, T. D., Chaudhuri, A. A., Newman, A., Stehr, H., Schroers-Martin, J., Chabon, J. J., … Diehn, M. (2017). Pretreatment Circulating Tumor DNA for Risk Stratification of Locally Advanced Esophageal Cancer Treated With Chemoradiation and Surgery. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S90–S91.
- Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
  Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., … Diehn, M. (2013). Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients
  Gentles, A., Alizadeh, A., Lee, S.-I., Shahbaba, B., Shachaf, C., Levy, R., … Plevritis, S. (2009). A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- The prognostic landscape of genes and infiltrating immune cells across human cancers
  Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., … Alizadeh, A. A. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)
  Scherer, F., Kurtz, D. M., Green, M. R., Newman, A. M., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
- Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., Zhou, L., … Alizadeh, A. A. (2015). Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.
  Kurtz, D. M., Green, M. R., Bratman, S. V., Liu, C.-L., Glover, C., Keane, C., … Alizadeh, A. A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
  Kurtz, D. M., Scherer, F., Green, M. R., Khodadoust, M. S., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas
  Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., … Natkunam, Y. (2017). KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 148(6), 465–76.
- Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas
  Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., & Natkunam, Y. (2013). Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas
  Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., & Natkunam, Y. (2013). Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation
  Jiang, X., Romero-Camarero, I., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., … Lossos, I. S. (2011). HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation. BLOOD. AMER SOC HEMATOLOGY.
- Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia
  Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., … Advani, A. S. (2011). Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. BLOOD, 118(21), 1095.
- Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.
  Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., … Alizadeh, A. A. (2014). Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), E4.
- Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
  Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., … Lowsky, R. (2012). Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. BLOOD, 120(21).
- Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma
  Kurtz, D. M., Scherer, F., Newman, A. M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., … Alizadeh, A. A. (2015). Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. BLOOD, 126(23).
- Circulating tumor DNA levels correlate with response to treatment in LMS patients
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., … van de Rijn, M. (2018). Circulating tumor DNA levels correlate with response to treatment in LMS patients. CLINICAL CANCER RESEARCH, 24(2), 38–39.
- Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
  Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., … Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- High-throughput sequencing for noninvasive disease detection in hematologic malignancies.
  Scherer, F., Kurtz, D. M., Diehn, M., & Alizadeh, A. A. (2017). High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 130(4), 440–52.
- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.
  Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies.
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246.
- High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.
  Logan, A. C., Su, R., George, T. I., Kohrt, H. E., Medeiros, B. C., & Alizadeh, A. A. (2009). High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis. BLOOD, 114(22), 554.
- Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA
  Esfahani, M. S., Newman, A. M., Scherer, F., Tibshirani, R., Diehn, M., & Alizadeh, A. A. (2016). Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. PROCEEDINGS OF THE 7TH ACM INTERNATIONAL CONFERENCE ON BIOINFORMATICS, COMPUTATIONAL BIOLOGY, AND HEALTH INFORMATICS, 516.
- Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations
  Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., … Alizadeh, A. A. (2016). Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. BLOOD. AMER SOC HEMATOLOGY.
- Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
  Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., … Alizadeh, A. A. (2016). Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA
  Scherer, F., Kurtz, D. M., Newman, A. M., Craig, A., Stehr, H., Zhou, L., … Alizadeh, A. A. (2016). Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. BLOOD, 128(22).
- The VarScan2's SNVs-Near-Indel Filter: Is It Necessary?
  Suarez, C. J., Stehr, H., Fung, E., Kunder, C. A., Ewalt, M. D., Lal, A., … Zehnder, J. (2015). The VarScan2's SNVs-Near-Indel Filter: Is It Necessary? JOURNAL OF MOLECULAR DIAGNOSTICS. ELSEVIER SCIENCE INC.
- A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes
  Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2010). A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. BLOOD, 116(21), 788.
- Circulating tumor DNA (ctDNA) in B-cell lymphoma
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.
- Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens
  Khodadoust, M., Olsson, N., Wagar, L., Chen, B., Rawson, K., Liu, C. L., … Alizadeh, A. A. (2016). Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer
  Dudley, J., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S., Liao, J., … Diehn, M. (2018). Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer. JOURNAL OF MOLECULAR DIAGNOSTICS, 20(6), 968.
- Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer
  Chen, E. L., Chaudhuri, A. A., Nabet, B. Y., Chabon, J. J., Merriott, D. J., Loo, B. W., … Diehn, M. (2018). Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), E676.
- Genomic Profiling of Bronchoalveolar Lavage Fluid in Patients with Non-Small Cell Lung Cancer
  Nair, V. S., Li, A. B.-H., Stehr, H., Chabon, J., Chaudhuri, A., Zhou, L., … Diehn, M. (2018). Genomic Profiling of Bronchoalveolar Lavage Fluid in Patients with Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197.
- B cell lymphomas present immunoglobulin neoantigens.
  Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2018). B cell lymphomas present immunoglobulin neoantigens. Blood.
- Detection and surveillance of bladder cancer using urine tumor DNA.
  Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., … Diehn, M. (2018). Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discovery.
- Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.
  Jin, M. C., Kurtz, D. M., Esfahani, M. S., Scherer, F., Craig, A. F. M., Soo, J., … Alizadeh, A. A. (2017). Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Reply to J. Wang et al.
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907.
- Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing
  Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., … Alizadeh, A. A. (2018). Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. BLOOD, 132.
- Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
  Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., … Alizadeh, A. A. (2018). Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. BLOOD, 132.
- Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling
  Mehrmohamadi, M., Esfahani, M. S., Soo, J., Scherer, F., Schroers-Martin, J. G., Chen, B., … Alizadeh, A. A. (2018). Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. BLOOD, 132.
- Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.
  Soo, J., Kurtz, D. M., Scherer, F., Craig, A. F. M., Jin, M. C., Westin, J. R., … Alizadeh, A. A. (2017). Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. JOURNAL OF CLINICAL ONCOLOGY, 35.
- Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.
  Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., … Levy, R. (2011). Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
- Genetic approaches using primary megakaryocytes to identify effectors of platelet integrin signaling
  Shattil, S. J., Bertoni, A., Eto, K., Murphy, R., Pampori, N., Shiraga, M., … Leavitt, A. D. (2001). Genetic approaches using primary megakaryocytes to identify effectors of platelet integrin signaling. MOLECULAR BIOLOGY OF THE CELL, 12, 270A.
- Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
  Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. (2016). Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY.
- BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma
  Natkunam, Y., Warnke, R., Alizadeh, A., Tibshirani, R., Horning, S., & van de Rijn, M. (2001). BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma. MODERN PATHOLOGY, 14(1), 173A.
- BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma
  Natkunam, Y., Warnke, R., Alizadeh, A., Tibshirani, R., Horning, S., & van de Rijn, M. (2001). BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma. LABORATORY INVESTIGATION, 81(1), 173A.
- Tumor Lesion Glycolysis as an Indicator of Prognosis in the pre-treatment Phase of Patients with DLBCL
  Flynt, L., Quon, A., Alizadeh, A., & Kurtz, D. (2016). Tumor Lesion Glycolysis as an Indicator of Prognosis in the pre-treatment Phase of Patients with DLBCL. JOURNAL OF NUCLEAR MEDICINE, 57.
- On the hunt for cancer neoantigens: is mass spectrometry the solution?
  Elias, J., Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Green, M. R., … Alizadeh, A. A. (2017). On the hunt for cancer neoantigens: is mass spectrometry the solution? MOLECULAR & CELLULAR PROTEOMICS. AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC.
- DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma
  Hartert, K., Tadros, S., Bouska, A., Moore, D., Pak, C., Heavican, T., … Green, M. R. (2016). DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. BLOOD, 128(22).
- Organocatalytic removal of formaldehyde adducts from RNA and DNA bases (vol 7, pg 752, 2015)
  Karmakar, S., Harcourt, E. M., Hewings, D. S., Scherer, F., Lovejoy, A. F., Kurtz, D. M., … Kool, E. T. (2015). Organocatalytic removal of formaldehyde adducts from RNA and DNA bases (vol 7, pg 752, 2015). NATURE CHEMISTRY, 7(12), 1033.
- Discovery of distinctive gene expression profiles in human arthritides by cDNA micro-array analysis
  Kraan, T. C. T. M. van der P., van Gaalen, F. A., Kasperkovitz, P., Verbeet, N., Alizadeh, A. A., Fero, M., … Verweij, C. L. (2002). Discovery of distinctive gene expression profiles in human arthritides by cDNA micro-array analysis. ARTHRITIS RESEARCH & THERAPY, 4.
- DNA microarrays as "microscopes" for watching a genome in action
  Brown, P. O., Botstein, D., Alizadeh, A., Derisi, J., Diehn, M., Eisen, M., … Staudt, L. (1998). DNA microarrays as "microscopes" for watching a genome in action. MOLECULAR BIOLOGY OF THE CELL, 9, 2A.
- Caspase-12 expression is markedly reduced in NF-E2(-/-)megakaryocytes and caspase-12(-/-) platelets exhibit a defect in integrin alpha IIb beta 3 inside-out signaling.
  Kerrigan, S. W., Murphy, R. P., Alizadeh, A., Diehn, M., Shattil, S. J., & Leavitt, A. D. (2002). Caspase-12 expression is markedly reduced in NF-E2(-/-)megakaryocytes and caspase-12(-/-) platelets exhibit a defect in integrin alpha IIb beta 3 inside-out signaling. BLOOD, 100(11), 13A.
- Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., & Arber, D. A. (2011). Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria. LABORATORY INVESTIGATION, 91, 328A.
- Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., & Arber, D. A. (2011). Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria. MODERN PATHOLOGY, 24, 328A.
- Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply
  Gentles, A. J., Majeti, R., & Alizadeh, A. A. (2011). Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 305(11), 1094.
- Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA
  Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Luikart, H., … Khush, K. (2019). Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 38(4), S12–S13.
- Genomic Feature Selection by Coverage Design Optimization.
  Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., & Tibshirani, R. (2018). Genomic Feature Selection by Coverage Design Optimization. Journal of Applied Statistics, 45(14), 2658–2676.
- Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+.
- Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA
  Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., … Diehn, M. (2017). Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
  Dudley, J. C., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S. B., Esfahani, M. S., … Diehn, M. (2019). Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. CANCER DISCOVERY, 9(4), 500–509.
- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst
  Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. COLD SPRING HARBOR MOLECULAR CASE STUDIES, 4(5).
- Determining cell type abundance and expression from bulk tissues with digital cytometry.
  Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., … Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology.
- Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., … van de Rijn, M. (2018). Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. CLINICAL CANCER RESEARCH, 24(11), 2688–99.
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+.
- B-cell lymphomas present immunoglobulin neoantigens
  Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2019). B-cell lymphomas present immunoglobulin neoantigens. BLOOD, 133(8), 878–81.
- Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.
  Azad, T. D., Chaudhuri, A., Newman, A. M., Stehr, H., Schroers-Martin, J., Chabon, J. J., … Diehn, M. (2017). Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq
  Shah, A. T., Azad, T. D., Chabon, J. J., Breese, M., Tanasa, B., Spillinger, A., … Sweet-Cordero, E. A. (2018). Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq. CANCER RESEARCH, 78(19).
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.
  Jain, N., Hartert, K., Tadros, S., Fiskus, W., Havranek, O., Ma, M. C., … Green, M. R. (2019). Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine, 11(497).
- Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma
  Kurtz, D. M., Scherer, F., Jin, M., Soo, J., Craig, A., Esfahani, M. S., … Alizadeh, A. A. (2017). Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study
  Kurtz, D. M., Jin, M., Soo, J., Scherer, F., Craig, A., Chabon, J. J., … Alizadeh, A. A. (2017). Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study. BLOOD. AMER SOC HEMATOLOGY.
- Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes
  Schroers-Martin, J. G., Kurtz, D. M., Soo, J., Jin, M., Scherer, F., Craig, A., … Alizadeh, A. A. (2017). Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes. BLOOD. AMER SOC HEMATOLOGY.
- Comparison of Circulating Tumor DNA Recovery from Plasma and Serum
  Soo, J., Kurtz, D. M., Jin, M., Scherer, F., Schroers-Martin, J. G., Esfahani, M. S., … Alizadeh, A. A. (2017). Comparison of Circulating Tumor DNA Recovery from Plasma and Serum. BLOOD. AMER SOC HEMATOLOGY.
- Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens
  Soo, J., Scherer, F., Kurtz, D. M., Schroers-Martin, J. G., Jin, M., Craig, A., … Alizadeh, A. A. (2017). Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens. BLOOD. AMER SOC HEMATOLOGY.
- Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes
  Jin, M., Kurtz, D. M., Esfahani, M. S., Soo, J., Craig, A., Scherer, F., … Alizadeh, A. A. (2017). Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes. BLOOD. AMER SOC HEMATOLOGY.
- Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.
  Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D. M., D'Emilio, N., & Grimm, D. R. (2018). Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification.
  Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D. M., D'Emilio, N., & Grimm, D. R. (2018). Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis
  Schroers-Martin, J. G., Scherer, F., Soo, J., Kurtz, D. M., Liu, C. L., Stehr, H., … Alizadeh, A. A. (2017). Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis. BLOOD. AMER SOC HEMATOLOGY.
- Noninvasive molecular subtyping and risk stratification of DLBCL.
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Noninvasive molecular subtyping and risk stratification of DLBCL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
  Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., … Alizadeh, A. A. (2019). Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell.
- Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
  Chabon, J. ., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., … Diehn, M. (2016). Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Determining cell type abundance and expression from bulk tissues with digital cytometry
  Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., … Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. NATURE BIOTECHNOLOGY, 37(7), 773-+.
- Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
  Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response
  Telli, M. L., Vinayak, S., Khododoust, M. S., Gruber, J. J., Ford, J. M., Sanchez, P., … Alizadeh, A. A. (2019). Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response. CANCER RESEARCH, 79(4).
- Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes
  Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2019). Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105(1), S113.
- ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
  Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., … Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Predicting HLA class II antigen presentation through integrated deep learning.
  Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., … Alizadeh, A. A. (2019). Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology.
- Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
  Nair, V., Hui, A. B.-Y., Chabon, J., Esfahani, M., Stehr, H., Nabet, B., … Diehn, M. (2019). Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(10), S747–S748.
- Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer.
  Azad, T. D., Chaudhuri, A. A., Fang, P., Qiao, Y., Esfahani, M. S., Chabon, J. J., … Diehn, M. (2019). Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology.
- Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
  Luca, B., Alizadeh, A., Diehn, M., Newman, A., Gentles, A., & Steen, C. (2019). Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC.
- HIGH PD-1 EXPRESSION AND SUPPRESSED EFFECTOR CYTOKINE SIGNALING DISTINGUISH T CELLS INFILTRATING FOLLICULAR LYMPHOMA TUMORS FROM PERIPHERAL T CELLS
  Myklebust, J. H., Irish, J., Brody, J., Czerwinski, D., Houot, R., Kohrt, H., … Levy, R. (2012). HIGH PD-1 EXPRESSION AND SUPPRESSED EFFECTOR CYTOKINE SIGNALING DISTINGUISH T CELLS INFILTRATING FOLLICULAR LYMPHOMA TUMORS FROM PERIPHERAL T CELLS. HAEMATOLOGICA, 97, 121.
- Functional significance of U2AF1 S34F mutations in lung adenocarcinomas.
  Esfahani, M. S., Lee, L. J., Jeon, Y.-J. J., Flynn, R. A., Stehr, H., Hui, A. B., … Diehn, M. (2019). Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 10(1), 5712.
- Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
  Alig, S., Macaulay, C., Kurtz, D. M., Ulrich, D., Andreas, H., Jin, M. C., … Alizadeh, A. A. (2019). Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. Blood.
- Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA
  Kurtz, D. M., Soo, J., Alig, S., Keh, L. C. T., Macaulay, C., Jin, M. C., … Alizadeh, A. A. (2019). Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. Blood.
- Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling
  Esfahani, M. S., Alig, S., Kurtz, D. M., Soo, J., Jin, M. C., Macaulay, C., … Alizadeh, A. A. (2019). Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. Blood.
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
  Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., … Alizadeh, A. A. (2019). Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood.
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
  Macaulay, C., Alig, S., Kurtz, D. M., Jin, M. C., Opat, S., Soo, J., … Alizadeh, A. A. (2019). Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. Blood.
- Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx.
  Steen, C. B., Liu, C. L., Alizadeh, A. A., & Newman, A. M. (2020). Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods in Molecular Biology (Clifton, N.J.), 2117, 135–57.
- Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.
  Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., … Diehn, M. (2020). Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
  Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., … Tran, P. T. (2020). Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology.
- Integrating genomic features for non-invasive early lung cancer detection
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. NATURE.
- Integrating genomic features for non-invasive early lung cancer detection.
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. Nature, 580(7802), 245–251.
- Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
  Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1.
- Functional significance of U2AF1 S34F mutations in lung adenocarcinomas
  Shahrokh Esfahani, M. (2019). Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 10.
- Detection of circulating tumor DNA in pancreas cancer
  King, D., Alizadeh, A. A., & Fisher, G. A. (2020). Detection of circulating tumor DNA in pancreas cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(4).
- Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma
  Shyam, R., Kurtz, D., Alig, S., Jin, M., Link, M., Marks, L., & Alizadeh, A. (2020). Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma. KLINISCHE PADIATRIE, 232(2), 81.
- ctDNA shedding dynamics dictate early lung cancer detection potential
  Avanzini, S., Kurtz, D. M., Chabon, J. J., Hori, S. S., Alizadeh, A. A., Diehn, M., & Reiter, J. G. (2020). ctDNA shedding dynamics dictate early lung cancer detection potential. CLINICAL CANCER RESEARCH, 26(11), 25.
- Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
  Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9).
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
  Steen, C. B., Luca, B. A., Esfahani, M. S., Nabet, B. Y., Sworder, B., Farshidfar, F., … Alizadeh, A. A. (2019). An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. BLOOD, 134.
- Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
  Garofalo, A., Schroers-Martin, J. G., Soo, J., Kurtz, D. M., Sworder, B., Liu, C. L., … Alizadeh, A. A. (2019). Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. BLOOD. AMER SOC HEMATOLOGY.
- Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
  Kathuria, K. R., Chen, B., Khodadoust, M. S., Olsson, N., Davis, M. M., Elias, J. E., … Alizadeh, A. A. (2019). Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation. BLOOD. AMER SOC HEMATOLOGY.
- Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma.
  Accomando, W. P., Rao, A. R., Hogan, D. J., Newman, A. M., Nakao, A., Alizadeh, A. A., … Ostertag, D. (2020). Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
  Alig, S., Jurinovic, V., Shahrokh Esfahani, M., Haebe, S., Passerini, V., Hellmuth, J. C., … Weigert, O. (2020). Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Advances, 4(18), 4451–62.
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
  Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell.
- KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
  Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer.
  Murciano-Goroff, Y. R., Hui, A. B., Chabon, J. J., Moding, E. J., Lebow, E. S., Araujo-Filho, J. A., … Diehn, M. (2020). Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
  Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Analytical validation of digital cytometry (iSort) for leukocyte enumeration using stored blood.
  Newman, A. M., Nakao, A., Li, K., Liu, C.-L., Mathi, K., Sigal, N., … Alizadeh, A. A. (2020). Analytical validation of digital cytometry (iSort) for leukocyte enumeration using stored blood. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
  Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery.
- A mathematical model of ctDNA shedding predicts tumor detection size.
  Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., … Reiter, J. G. (2020). A mathematical model of ctDNA shedding predicts tumor detection size. Science Advances, 6(50).
- Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
  Wisdom, A. J., Mowery, Y. M., Hong, C. S., Himes, J. E., Nabet, B. Y., Qin, X., … Kirsch, D. G. (2020). Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature Communications, 11(1), 6410.
- Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
  Wagar, L. E., Sworder, B., Khodadoust, M. S., Davis, M. M., & Alizadeh, A. A. (2019). Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment. BLOOD. AMER SOC HEMATOLOGY.
- Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
  Luca, B. A., Steen, C. B., Azizi, A., Matusiak, M., Przybyl, J., Neishaboori, N., … Newman, A. M. (2020). Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
  Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Chromatin accessibility patterns in cell-free DNA reveal tumor heterogeneity
  Esfahani, M. S., Mehrmohamadi, M., Steen, C. B., Hamilton, E. G., King, D. A., Soo, J., … Alizadeh, A. A. (2020). Chromatin accessibility patterns in cell-free DNA reveal tumor heterogeneity. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Analytical validation of iSort digital cytometry for leukocyte enumeration in clinical tumor specimens.
  Newman, A. M., Nakao, A., Li, K., Wilson, D. C., Liu, C.-L., Diehn, M., & Alizadeh, A. A. (2020). Analytical validation of iSort digital cytometry for leukocyte enumeration in clinical tumor specimens. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
  Alig, S., Macaulay, C. W., Kurtz, D. M., Dührsen, U., Hüttmann, A., Schmitz, C., … Alizadeh, A. A. (2021). Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2002573.
- Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
  Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
  Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Higher-grade transformed follicle center lymphomas (FCL): Gene expression profiling comparison to pre-transformed FCL and to de novo diffuse large B-cell lymphomas (DLBCL).
  Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Brown, P. O., Botstein, D., & Levy, R. (2001). Higher-grade transformed follicle center lymphomas (FCL): Gene expression profiling comparison to pre-transformed FCL and to de novo diffuse large B-cell lymphomas (DLBCL). BLOOD. AMER SOC HEMATOLOGY.
- Gene expression profiling of rheumatoid synovitis using cDNA microarrays.
  Verweij, C. L., van der Kraan, C. T., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., … Brown, P. O. (2000). Gene expression profiling of rheumatoid synovitis using cDNA microarrays. ARTHRITIS AND RHEUMATISM. LIPPINCOTT WILLIAMS & WILKINS.
- Distinct IL-4 intracellular signaling in germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma: Novel opportunities for therapeutic interventions.
  Lossos, I. S., Lu, X. Q., Ding, F. Y., Rosado, M., Alizadeh, A. A., & Nechushtan, H. (2004). Distinct IL-4 intracellular signaling in germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma: Novel opportunities for therapeutic interventions. BLOOD. AMER SOC HEMATOLOGY.
- Next Generation Sequencing of Cerebrospinal Fluid to Improve Diagnostic Sensitivity, Detect Spatial Heterogeneity, and Predict Outcomes for Advanced Lung Cancer Patients with Leptomeningeal Carcinomatosis
  Azad, T., Nanjo, S., Chabon, J., Jin, M., Connolly, I., Ko, R., … Diehn, M. (2020). Next Generation Sequencing of Cerebrospinal Fluid to Improve Diagnostic Sensitivity, Detect Spatial Heterogeneity, and Predict Outcomes for Advanced Lung Cancer Patients with Leptomeningeal Carcinomatosis. JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS.
- Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance
  Jeong, Y., Ngoc Hoang, Stehr, H., Lovejoy, A., Gentles, A., Chaudhuri, A., … Diehn, M. (2017). Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome
  Chen, B., Khodadoust, M., Olsson, N., Fast, E., Wagar, L. E., Liu, C. L., … Alizadeh, A. A. (2017). Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
  Chaudhuri, A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).
  Diehn, M., Alizadeh, A. A., Adams, H.-P., Lee, J. J., Klassen, S., Palma, J. F., … Pross, M. (2017). Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Antigen presentation profiling reveals T-cell recognition of lymphoma imrnunoglobuhn neoantigens
  Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Haabeth, O. A. W., Chen, B., … Elias, J. E. (2017). Antigen presentation profiling reveals T-cell recognition of lymphoma imrnunoglobuhn neoantigens. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.
- Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.
  Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A. F. M., Khodadoust, M. S., Lovejoy, A. F., … Alizadeh, A. A. (2016). Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
  Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., … Hamid, O. (2016). A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS.
- Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence for the existence of distinctive pathways relevant to disease
  Kasperkovitz, P., Verbeet, N. L., Smeets, T., Tak, P. P., Huizinga, T., Baltus, B., … Verweij, C. L. (2004). Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence for the existence of distinctive pathways relevant to disease. ARTHRITIS RESEARCH & THERAPY. BIOMED CENTRAL LTD.
- Prediction of survival in diffuse large B-Cell lymphoma (DLBCL) based on the expression of six genes.
  Lossos, L. S., Czerwinski, D., Tibshirani, R., Wechser, M., Alizadeh, A. A., Botstein, D., & Levy, R. (2003). Prediction of survival in diffuse large B-Cell lymphoma (DLBCL) based on the expression of six genes. BLOOD. AMER SOC HEMATOLOGY.
- The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.
  Pachynski, R., Zabel, B., Monnier, J., Gentles, A., Swanson, C., Kohrt, H., … Butcher, E. (2013). The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM
  Myklebust, J. H., Brody, J., Alizadeh, A. A., Czerwinski, D. K., Kolstad, A., Green, M. R., … Levy, R. (2013). Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. BLOOD. AMER SOC HEMATOLOGY.
- Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy
  Yang, J., & Du, X. (2013). Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. SURGICAL ONCOLOGY-OXFORD, 22(3), E53–E57.
- Comparison of molecular abnormalities in bronchial brushings and tumor touch preps: The potential use of fluorescence in situ hybridization (FISH) as a predictive marker in early stage lung carcinomas
  Barkan, G. A., Caraway, N. P., Zaidi, T., Alizadeh, A., Johnston, D., Jiang, F., & Katz, R. L. (2003). Comparison of molecular abnormalities in bronchial brushings and tumor touch preps: The potential use of fluorescence in situ hybridization (FISH) as a predictive marker in early stage lung carcinomas. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- GAL is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.
  Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., & Levy, R. (2002). GAL is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Distinctive gene expression profiles in synovial tissue from rheumatoid arthritis patients by cDNA microarray analysis.
  Kraan, T. C., van Gaalen, F. A., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., … Verweij, C. L. (2002). Distinctive gene expression profiles in synovial tissue from rheumatoid arthritis patients by cDNA microarray analysis. ARTHRITIS AND RHEUMATISM. WILEY.
- Rheumatoid arthritis is a heterogeneous disease: Discovery of distinctive gene expression profiles in rheumatoid synovia.
  Verweij, C. L., Kraan, T. T., van Gaalen, F. A., Kasperkovitz, P. V., Smeets, T. J., Alizadeh, A. A., … Brown, P. O. (2002). Rheumatoid arthritis is a heterogeneous disease: Discovery of distinctive gene expression profiles in rheumatoid synovia. ARTHRITIS AND RHEUMATISM. WILEY.
- Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy
  Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., … Natkunam, Y. (2011). Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy
  Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., … Natkunam, Y. (2011). Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Discovery of distinctive gene expression profiles in human arthritides by cDNA microarray analysis.
  Verweij, C. L., Kraan, T. C., van Galen, F., Alizadeh, A. A., Fero, M., Huizinga, T. W., … Brown, P. O. (2001). Discovery of distinctive gene expression profiles in human arthritides by cDNA microarray analysis. ARTHRITIS AND RHEUMATISM. WILEY-LISS.
- Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation
  Yang, Y. H., Dudoit, S., Luu, P., Lin, D. M., Peng, Ngai, J., & Speed, T. P. (2002). Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. NUCLEIC ACIDS RESEARCH, 30(4), e15.
- Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation (vol 99, pg 11796, 2002)
  Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., … Brown, P. O. (2002). Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation (vol 99, pg 11796, 2002). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(23), 15245.
- Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
  Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., … Alizadeh, A. A. (2021). Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology.
- A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas.
  Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., … Sweet-Cordero, E. A. (2021). A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas. Molecular Cancer Therapeutics.
- Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
  Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183.
- Atlas of clinically distinct cell states and ecosystems across human solid tumors.
  Luca, B. A., Steen, C. B., Matusiak, M., Azizi, A., Varma, S., Zhu, C., … Newman, A. M. (2021). Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell.
- The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.
  Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., … Alizadeh, A. A. (2021). The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell.
- SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.
  Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchietti, L., Alizadeh, A. A., … Smith, S. M. (2021). SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of Geriatric Oncology.
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
  Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021). Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discovery.
- Phased variants improve DLBCL minimal residual disease detection at the end of therapy.
  Kurtz, D. M., Chabon, J. J., Soo, J., Keh, L. C. T., Alig, S., Schultz, A., … Alizadeh, A. A. (2021). Phased variants improve DLBCL minimal residual disease detection at the end of therapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.
  Moding, E. J., Hui, A. B., Murciano-Goroff, Y. R., Nabet, B., Schultz, A., Qiao, Y., … Diehn, M. (2021). Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
  Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery.
- Circulating Tumor DNA in Lymphoma: Principles and Future Directions.
  Roschewski, M., Rossi, D., Kurtz, D. M., Alizadeh, A. A., & Wilson, W. H. (1800). Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discovery, 3(1), 5–15.
- Circulating tumor DNA profiling for noninvasive detection, classification, and risk stratification of patients with CNS lymphomas
  Mutter, J. A., Alig, S., Lauer, E. M., Esfahani, M. S., Mitschke, J., Kurtz, D. M., … Scherer, F. (2021). Circulating tumor DNA profiling for noninvasive detection, classification, and risk stratification of patients with CNS lymphomas. ONCOLOGY RESEARCH AND TREATMENT. KARGER.
- Inferring gene expression from cell-free DNA fragmentation profiles.
  Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., … Alizadeh, A. A. (2022). Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology.
- Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.
  Kurtz, D. M., Chabon, J. J., Sworder, B., Keh, L. C. T., Soo, J., Alig, S., … Diehn, M. (2021). Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
  Spasevska, I., Josefsson, S., Blaker, Y. N., Steen, C. B., Sharma, A., Kushekhar, K., … Myklebust, J. H. (2020). Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage
  Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., … Alizadeh, A. A. (2020). Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. BLOOD. AMER SOC HEMATOLOGY.
- Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma
  Greenwell, I. B., Switchenko, J. M., Maddocks, K. J., Kahl, B. S., Craig, A. F. M., Alizadeh, A. A., … Cohen, J. B. (2020). Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)
  Shukla, N. D., Craig, A. F. M., Sworder, B., Kurtz, D. M., Macaulay, C., Garofalo, A., … Alizadeh, A. A. (2020). Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). BLOOD. AMER SOC HEMATOLOGY.
- CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering
  Majzner, R. G., Frank, M. J., Mount, C., Tousley, A., Kurtz, D. M., Sworder, B., … Mackall, C. L. (2020). CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. BLOOD. AMER SOC HEMATOLOGY.
- Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA.
  Yaung, S. J., Woestmann, C., Ju, C., Ma, X. M., Gattam, S., Zhou, Y., … Muley, T. (2022). Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers, 14(10).
- Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
  Yang, L. M., Costales, C., Ramanathan, M., Bulterys, P. L., Murugesan, K., Schroers-Martin, J., … Banaei, N. (2022). Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 153, 105217.
- Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.
  Nair, V. S., Hui, A. B., Chabon, J. J., Shahrokh Esfahani, M., Stehr, H., Nabet, B. Y., … Diehn, M. (2022). Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. Cancer Research.
- Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.
  de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Dogan, A., … Scott, D. W. (2022). Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. Blood.
- Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
  Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma
  Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., … Gopal, A. K. (2021). Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing
  Esfahani, M. S., Alig, S., Mehrmohamadi, M., Hamilton, E. G., King, D. A., Schultz, A., … Alizadeh, A. A. (2021). Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. BLOOD. AMER SOC HEMATOLOGY.
- S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements
  Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchietti, L., Alizadeh, A. A., … Smith, S. M. (2021). S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. BLOOD. AMER SOC HEMATOLOGY.
- Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib
  Roschewski, M., Phelan, J. D., Pittaluga, S., Melani, C., Lakhotia, R., Chabon, J. J., … Wilson, W. H. (2021). Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib. BLOOD. AMER SOC HEMATOLOGY.
- Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
  Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S., Blaker, Y. N., Rustad, E. H., … Myklebust, J. H. (2021). Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis
  Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., … Alizadeh, A. A. (2021). Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. BLOOD. AMER SOC HEMATOLOGY.
- Molecular Monitoring of Lymphomas.
  Schroers-Martin, J. G., Alig, S., Garofalo, A., Tessoulin, B., Sugio, T., & Alizadeh, A. A. (2022). Molecular Monitoring of Lymphomas. Annual Review of Pathology.
- Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non-small cell lung cancer.
  Jun, S., Shukla, N., Durm, G. A., Hui, A. B., Cao, S., Kunder, C., … Diehn, M. (2022). Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
  Cherng, H.-J. J., Alig, S., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., … Westin, J. (2022). Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
  Cherng, H.-J. J., Alig, S., Oki, Y., Nastoupil, L. J., Fayad, L. E., Neelapu, S. S., … Westin, J. R. (2022). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances.
- Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas.
  Lynch, R. C., Poh, C., Ujjani, C. S., Warren, E. H., Smith, S. D., Shadman, M., … Gopal, A. K. (2022). Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Advances.
- Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
  Mutter, J. A., Alig, S. K., Esfahani, M. S., Lauer, E. M., Mitschke, J., Kurtz, D. M., … Scherer, F. (2022). Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2200826.
- Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
  Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., … Alizadeh, A. A. (2022). Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell.
- Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.
  Obeid, J.-P. P., Hiniker, S. M., Schroers-Martin, J., Guo, H. H., No, H. J., Moding, E. J., … Binkley, M. S. (2023). Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas. EJHaem, 4(1), 90–99.
- Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., & Arber, D. A. (2014). Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 142(6), 803–808.
- Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
  Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2022). Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
  Garofalo, A., Alig, S. K., Schroers-Martin, J., Shyam, R. M., Olsen, M., Kurtz, D. M., … Alizadeh, A. A. (2022). Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas. BLOOD. AMER SOC HEMATOLOGY.
- Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
  Alig, S. K., Esfahani, M. S., Li, M. Y., Adams, R. M., Garofalo, A., Jin, M. C., … Alizadeh, A. A. (2022). Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling. BLOOD. AMER SOC HEMATOLOGY.
- Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
  Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., … Gopal, A. K. (2022). Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume. BLOOD. AMER SOC HEMATOLOGY.
- Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
  Schroers-Martin, J., Garofalo, A., Soo, J., Boegeholz, J., Alig, S. K., Sworder, B., … Alizadeh, A. A. (2022). Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders. BLOOD. AMER SOC HEMATOLOGY.
- Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
  Shukla, N. D., Schroers-Martin, J., Kathuria, K. R., Sworder, B., Alig, S. K., Frank, M. J., … Alizadeh, A. A. (2022). Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS. BLOOD. AMER SOC HEMATOLOGY.
- Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
  Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., … Alizadeh, A. A. (2022). Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY.
- Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
  Kurtz, D. M., Hogan, G. J., Schultz, A., Kopeckova, K., Kuffer, C., Blair, D., … Westin, J. (2022). Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP. BLOOD. AMER SOC HEMATOLOGY.
- MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
  Roschewski, M., Kurtz, D. M., Westin, J., Lynch, R. C., Macaulay, C., Kuffer, C., … Schultz, A. (2022). MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design. BLOOD. AMER SOC HEMATOLOGY.
- Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
  Kurtz, D. M., Ahmed, S., Tong, C. K., Mei, M., Ding, C., Flinn, I. W., … Horak, I. D. (2022). Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial). BLOOD. AMER SOC HEMATOLOGY.
- Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY.
- Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study
  Mosquera, A. P., Hosoya, H., Jin, M. C., Esfahani, M. S., Schroers-Martin, J., Sworder, B., … Alizadeh, A. A. (2022). Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study. BLOOD. AMER SOC HEMATOLOGY.
- Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.
  Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., … Gopal, A. K. (2023). Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood.
- Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
  Boegeholz, J., Alig, S. K., Sworder, B., Schroers-Martin, J., Macaulay, C., Craig, A. F. M., … Alizadeh, A. A. (2022). Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy. BLOOD. AMER SOC HEMATOLOGY.
- Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma
  Greenwell, I. B., Switchenko, J. M., Craig, A. F. M., Alizadeh, A. A., Allen, P. B., Escobar, A., … Algave, M. (2022). Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment.
  Swanson, K., Wu, E., Zhang, A., Alizadeh, A. A., & Zou, J. (2023). From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell.
- Profiling Cellular Ecosystems at Single-Cell Resolution and at Scale with EcoTyper.
  Steen, C. B., Luca, B. A., Alizadeh, A. A., Gentles, A. J., & Newman, A. M. (2023). Profiling Cellular Ecosystems at Single-Cell Resolution and at Scale with EcoTyper. Methods in Molecular Biology (Clifton, N.J.), 2629, 43–71.
- Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors.
  Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B. J., … Alizadeh, A. A. (2023). Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors. Cancer Discovery.
- Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.
  Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., … Stehr, H. (2023). Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma. Journal of Cutaneous Pathology.
- Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.
  Johansson, P., Alig, S., Richter, J., Hanoun, C., Rekowski, J., Durig, J., … Huttmann, A. (2023). Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. Annals of Hematology.
- Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.
  Palmer, A. C., Kurtz, D. M., & Alizadeh, A. A. (2023). Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin. The New England Journal of Medicine, 389(8), 764–766.
- Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
  Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S. E., Blaker, Y. N., Kolstad, A., … Myklebust, J. H. (2023). Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Advances.
- Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
  Lauer, E. M., Riegler, E., Mutter, J. A., Alig, S. K., Bleul, S., Kuehn, J., … Scherer, F. (2023). Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas. Neuro-Oncology.
- A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.
  Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2023). A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis. Blood Advances.
- Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq
  Isbell, J. M., Li, B. T., Razavi, P., Reis-Filo, J., Liu, S.-Y., Selenica, P., … Diehn, M. (2023). Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Improved cfDNA methylation profiling through correction of misrepaired jagged-ends
  Wang, R., Hamilton, E. G., Hui, A., Almanza, D., Esfahani, M. S., Diehn, M., & Alizadeh, A. A. (2023). Improved cfDNA methylation profiling through correction of misrepaired jagged-ends. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
  Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., … Alizadeh, A. A. (2023). Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature.
- Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas.
  Shukla, N., Schroers-Martin, J., Sworder, B., Kathuria, K. R., Alig, S., Frank, M. J., … Alizadeh, A. A. (2023). Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas. Blood Advances.
- A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
  Kastenschmidt, J. M., Schroers-Martin, J. G., Sworder, B. J., Sureshchandra, S., Khodadoust, M. S., Liu, C. L., … Alizadeh, A. A. (2024). A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. Cell Stem Cell.
- CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
- Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods
  Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., … Alizadeh, A. A. (2023). Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods. BLOOD. AMER SOC HEMATOLOGY.
- Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas
  Nagy, A., Batai, B., Hogan, G., Chabon, J. J., Troke, M., Riley, L., … Bodor, C. (2023). Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas. BLOOD. AMER SOC HEMATOLOGY.
- An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring
  Sugio, T., Shukla, N., Khodadoust, M. S., Nesselbush, M., Kato, K., Alig, S. K., … Alizadeh, A. A. (2023). An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring. BLOOD. AMER SOC HEMATOLOGY.
- End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA
  Roschewski, M., Lindenberg, L., Mena, E., Lakhotia, R., Melani, C., Steinberg, S. M., … Wilson, W. H. (2023). End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA. BLOOD. AMER SOC HEMATOLOGY.
- Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification
  Mutter, J. A., Esfahani, M. S., Schroers-Martin, J., Alig, S. K., Hamilton, M. P., Sworder, B. J., … Alizadeh, A. A. (2023). Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification. BLOOD. AMER SOC HEMATOLOGY.
- Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study
  Sworder, B. J., Yoon, S. E., Kim, S. J., Schultz, A., Hogan, G., Close, S., … Kim, W. S. (2023). Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study. BLOOD. AMER SOC HEMATOLOGY.
- Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy
  Goldstein, J., Kim, W. S., Yoon, S. E., Kim, S. J., Roschewski, M., Westin, J., … Kurtz, D. M. (2023). Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy. BLOOD. AMER SOC HEMATOLOGY.
- Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma
  Schroers-Martin, J., Mutter, J. A., Esfahani, M. S., Scherer, F., Soo, J., Alig, S. K., … Alizadeh, A. A. (2023). Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study
  Stepan, L., Ansari, S., Okal, A., Dell'Aringa, J., Thompson, E., Crotta, A., … Peiser, L. (2023). Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study. BLOOD. AMER SOC HEMATOLOGY.
- Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma
  Su, S., Subramanian, A., Flerlage, T., Flerlage, J. E., Alig, S. K., Moding, E. J., … Binkley, M. S. (2023). Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab plus AVD
  Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., … Gopal, A. K. (2023). Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab plus AVD. BLOOD. AMER SOC HEMATOLOGY.
- Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults
  Rossi, C., Boegeholz, J., Alig, S. K., Garofalo, A., Esfahani, M. S., Schroers-Martin, J., … Alizadeh, A. A. (2023). Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults. BLOOD. AMER SOC HEMATOLOGY.
- Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Kurtz, D. M., Hogan, G., Schultz, A., Chabon, J. J., Alizadeh, A. A., Havenith, K., … Pantano, S. (2023). Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances.
- Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
  Azad, T. D., Nanjo, S., Jin, M. C., Chabon, J. J., Kurtz, D. M., Chaudhuri, A. A., … Diehn, M. (2024). Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. NPJ Precision Oncology, 8(1), 121.
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
  Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., … Miklos, D. B. (2024). Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. The New England Journal of Medicine, 390(22), 2047–2060.
- ViPOR's Venom - Rationally Targeting DLBCL with Precision.
  Goldstein, J. S., & Alizadeh, A. A. (2024). ViPOR's Venom - Rationally Targeting DLBCL with Precision. The New England Journal of Medicine, 390(23), 2209–2211.
- Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
  Jun, S., Shukla, N. A., Durm, G., Hui, A. B., Cao, S., Ganti, A. K., … Diehn, M. (2024). Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
  Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Adams, R., … Alizadeh, A. A. (2023). 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematological Oncology, 41 Suppl 2, 96–98.
- 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
  Rossi, C., Boegeholz, J. L., Alig, S. K., Garofolo, A., Esfahani, M. S., Schroers-Martin, J., … Alizadeh, A. A. (2023). 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematological Oncology, 41 Suppl 2, 321–322.
- Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)
  Isbell, J. M., Goldstein, J. S., Hamilton, E. G., Liu, S.-Y., Eichholz, J., Buonocore, D. J., … Diehn, M. (2024). Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.
  Hamilton, M. P., Miklos, D. B., & Alizadeh, A. A. (2024). Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply. The New England Journal of Medicine, 391(9), 870–871.
- Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.
  Murciano-Goroff, Y. R., Hui, A. B.-Y., Araujo Filho, J. A., Hamilton, E. G., Chabon, J. J., Moding, E. J., … Diehn, M. (2024). Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. JCO Precision Oncology, 8, e2400216.
- Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
  Hamilton, M. P., & Alizadeh, A. A. (2024). Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies. Transplantation and Cellular Therapy, 30(10), 936–938.
- ULTRASENSITIVE URINARY LIQUID BIOPSY ANALYSIS FOR BCG RESPONSE ASSESSMENT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
  Shi, W. Y., Liu, K. J., Esfahani, M. S., Schroers-Martin, J. G., Nesselbush, M., Chen, S. B., … Diehn, M. (2024). ULTRASENSITIVE URINARY LIQUID BIOPSY ANALYSIS FOR BCG RESPONSE ASSESSMENT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Cell-Free DNA in Hematologic Malignancies.
  Schroers-Martin, J. G., & Alizadeh, A. A. (2024). Cell-Free DNA in Hematologic Malignancies. JCO Oncology Practice, 20(11), 1491–1499.
- Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis
  Nanjo, S., Azad, T., Jin, M., Yano, S., Hui, A., Nagpal, S., … Diehn, M. (2024). Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Specializing In

Blood Test
Cancer Genetic Testing
Cancer Risk Assessment with Genetic Testing and Counseling
Cutaneous Lymphoma

Practice Locations

Lymphoma Program Palo Alto, CA

Palo Alto, CA

Lymphoma Program

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Lymphoma Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Lymphoma Program in Palo Alto

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(21 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

5.0/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(87 reviews)

The doctor and all of the staff were great. PA Sam Kramer has been outstanding with her knowledge and explanation of everything. It makes going through this much less stressful.

Nov 2024

•

Verified SHC Patient

Excellent visit!

Oct 2024

•

Verified SHC Patient

All staff with whom I interacted were courteous, caring, professional, and kind.

Oct 2024

•

Verified SHC Patient

As ever, I appreciate Dr. Alizadeh and his team, and the excellent care they provide!

Oct 2024

•

Verified SHC Patient

The doctor was very good at communicating to me what my blood levels would mean if things were to change and what medications possibilities there would be in the future if my current medication stops working

Oct 2024

•

Verified SHC Patient

This man is genuine in his concerns and he always makes me feel like I am the most important person he needs to speak with. All doctors should be like him.

Sep 2024

•

Verified SHC Patient

I felt like he wanted to get more involved with my care

Sep 2024

•

Verified SHC Patient

Fantastic doctor! Thank You!

Aug 2024

•

Verified SHC Patient

Thank you for your professionalism and your help with my condition.

Jul 2024

•

Verified SHC Patient

Dr. Alizadeh is amazingly warm, personable and caring. Heâ€™s a wonderful man who clearly cares for his patients.

Jul 2024

•

Verified SHC Patient

Dr. Alizadeh is a fantastic, focused, superbly knowledgeable and caring doctor that Iâ€™m grateful is handling my case.

May 2024

•

Verified SHC Patient

Stanford continues to demonstrate it's high level of medical superiority via it's doctors and staff

Apr 2024

•

Verified SHC Patient

He is an excellent doctor.

Mar 2024

•

Verified SHC Patient

Would never consider any other doctor for my condition, always cared treated well. Feel would not exist without his care.

Feb 2024

•

Verified SHC Patient

Iâ€™m so thankful that Dr Alizadeh is one of my doctors. Iâ€™m so thankful that he recommended the pills.

Dec 2023

•

Verified SHC Patient

He is terrific! Glad to have him back after his sabbatical, although Brian was great too.

Dec 2023

•

Verified SHC Patient

Fantastic doctor!

Nov 2023

•

Verified SHC Patient

Heâ€™s a very good doctor and I am thankful to have him taking care of me.

Nov 2023

•

Verified SHC Patient

Dr. Alizadeh is great. I look forward to seeing him again in the future.

Sep 2023

•

Verified SHC Patient

All Stanford doctors are the very best.

Sep 2023

•

Verified SHC Patient

I appreciated the way in which Dr. Alizadah explained to me in detail the issues Iâ€™m facing, in a manner which I could easily understand. I would highly recommend him and anyone on his team for medical care i his field of study.

Aug 2022

•

Verified SHC Patient

Both Dr Alizadeh and Dr Hamilton are the best. So thorough, and knowledgeable, and pleasant. Iâ€™m so thankful they are my doctors. I feel Iâ€™m getting the best of care.

Jul 2022

•

Verified SHC Patient

Dr. Alizadeh itâ€™s one of the best oncologist Stanford has, I will recommend anybody who have my problem to him, I hope God keep him for a long Time in this world.

Jun 2022

•

Verified SHC Patient

Always a Great Visit. Very Knowledgeable Staff.

May 2022

•

Verified SHC Patient

He is kind and compassionate and knowledgeable. He is the BEST!

May 2022

•

Verified SHC Patient

Treated with such professionalism and come from the young man at the front door to the Sam, Dr. Elizadeh and MYra

Apr 2022

•

Verified SHC Patient

Excellent doctor, confident with Stanford. He also had a great fellow MD who preceded my visit with Dr. Alizadeh. Very thorough. (Dr. Mark Hamilton)

Apr 2022

•

Verified SHC Patient

The care I have received at Stanford has always been professional in every way, but also very attentive and compassionate. Dr Alizadeh and his team are excellent.

Apr 2022

•

Verified SHC Patient

Fantastic doctor. I feel fortunate that he will treat me!

Apr 2022

•

Verified SHC Patient

very thorough, compassionate and kind.

Mar 2022

•

Verified SHC Patient

Would recommend it anytime they are the best.

Mar 2022

•

Verified SHC Patient

As always the Stanford medical staff are the best! Not only are they medically outstanding their care and compassion shine through!

Mar 2022

•

Verified SHC Patient

He is superb.

Mar 2022

•

Verified SHC Patient

All was cool!

Mar 2022

•

Verified SHC Patient

Drs. Sworder and Alizadeh are excellent. They listened to my concerns and came up with a good plan. I have great faith in the clinical knowledge and the application of that knowledge to medical care. They are wonderful, caring doctors.

Feb 2022

•

Verified SHC Patient

I am always impressed by the level of care here.

Feb 2022

•

Verified SHC Patient

I was given Clear, Concise information regarding my prognosis.

Jan 2022

•

Verified SHC Patient

I couldnâ€™t have more appreciative my visit with Both DR. Arash and DR. Sworder who took time explaining test results and allowed time for questions and answers that is so relieving. They both made me feel special with their compassionate and warm treatment. Thank you

Jan 2022

•

Verified SHC Patient

Dr Alizadeh and Dr Hamilton are exceptional on all levels -- medically as well as their overall, personal care for me as a patient.

Jan 2022

•

Verified SHC Patient

Amazing doctor! Canâ€™t ask for anything more!

Jan 2022

•

Verified SHC Patient

He and his staff, including Sam are top notch and wonderful.

Dec 2021

•

Verified SHC Patient

Dr. Alizadeh and Dr. Sworder are always professional, informative and fun. My visits with them are always enjoyable.

Dec 2021

•

Verified SHC Patient

Dr. Alizadeh is a very caring and compassionate individual that always combines his expert knowledge for the best outcome taking into consideration a patients individual needs. Great doctor and highly respect him !!

Oct 2021

•

Verified SHC Patient

Outstanding provider and team.

Sep 2021

•

Verified SHC Patient

The fellow who worked with Dr. Alizadeh, Dr. Beigi is very nice. She spent a lot of time in checking out the patient.

Dec 2019

•

Verified SHC Patient

Dr. Alizadeh is an excellent clinician. I really appreciate his caring method and clear responses to questions. I feel honored to receive my care from Dr. Alizadeh and his fellows.

Nov 2019

•

Verified SHC Patient

Dr. Alizadeh & team are excellent. I have ultimate trust in them to make the right discussions in collaboration with me. The best!

Aug 2019

•

Verified SHC Patient

Dr. Alizadeh is outstanding. He knows my case and does his best to help. I am very grateful for Dr. Alizadeh's care.

May 2019

•

Verified SHC Patient

Very professional and very patient with our questions.

Feb 2019

•

Verified SHC Patient

Dr. Alizadeh is outstanding. I feel I am receiving state-of-the-art care with him. His personality is great - welcoming and caring.

Feb 2019

•

Verified SHC Patient

Very good does not accurately describe my feelings. It should be outstanding!! Great staff, great experience.

Dec 2018

•

Verified SHC Patient

I have a Ph'D in biology/genetics from Stanford- conversations were very informative.

Nov 2018

•

Verified SHC Patient

Drs. Sworden & Alizadeh are outstanding. They know my case and go above & beyond to answer my questions and provide excellent care.

Oct 2018

•

Verified SHC Patient

I'm very impressed with Dr. Alizadeh.

Sep 2018

•

Verified SHC Patient

Very good.

Jul 2018

•

Verified SHC Patient

Dr. Alizadeh & fellow Dr. Sworder always listen carefully to my questions and carefully explain the answers. They are willing to use state of the art tests to get the best answers. World class care!

Jun 2018

•

Verified SHC Patient

We were extremely impressed with Dr. Martin & Dr. Alizadeh. They came prepared for our initial meeting, explained our options and seemed genuinely concerned about our son's case.

May 2018

•

Verified SHC Patient

I'm always impressed by the knowledge & concern Dr. Alizadeh and Dr. Kurty have with my overall health as well as my lymphoma.

Oct 2017

•

Verified SHC Patient

Excellent oncologist. Willing to explore various approaches to understand & investigate my clinical status. Very pleased!!

Aug 2017

•

Verified SHC Patient

Dr. Alizadeh is a great lymphoma specialist with great manner.

Jun 2017

•

Verified SHC Patient

Dr. Alizadeh remembered all the details of my case from 8 years ago. He answered my question on annual appointments - to check for side effects of the chemotherapy. Excellent doctor.

Mar 2017

•

Verified SHC Patient

Dr. Ash is very professional and thorough. We like him a lot.

Jan 2017

•

Verified SHC Patient

Added test for a major problem I was having though not in his field. Was concerned enough to suggest test and called with results.

Nov 2016

•

Verified SHC Patient

Have the utmost confidence and respect for this doctors opinions and direction.

Oct 2016

•

Verified SHC Patient

Very satisfied.

Aug 2016

•

Verified SHC Patient

I came to Stanford for a second opinion. I stayed with Dr. Alizadeh's practice because of the confidence I have in him and his team.

Apr 2016

•

Verified SHC Patient

Always an excellent experience takes time to address my specific needs and life beyond treatment.

Mar 2016

•

Verified SHC Patient

Tremendous staff.

Mar 2016

•

Verified SHC Patient

Dr. Alizadeh & his staff are friendly concerned & helpful. I couldn't ask for a better team.

Feb 2016

•

Verified SHC Patient

ALways good.

Feb 2016

•

Verified SHC Patient

Excellent! I really appreciate the amount of transparency in my treatment and the Dr's regard for my concerns. I 100% trust him to provide me with the highest level of care.

Nov 2015

•

Verified SHC Patient

Always great visits.

Oct 2015

•

Verified SHC Patient

She is a gem!

Oct 2015

•

Verified SHC Patient

Everyone was professional.

Aug 2015

•

Verified SHC Patient

I have great confidence in Dr. Alizadeh.

Jul 2015

•

Verified SHC Patient

Very pleasant & informative.

Jul 2015

•

Verified SHC Patient

Dr. Alizadeh is a great researcher.

Jun 2015

•

Verified SHC Patient

No bad expereince.

Apr 2015

•

Verified SHC Patient

I very very much like Dr. Alizadeh. He takes all the time I need never makes me feel he's rushing. He is so considerate as if I were his only patient, and I total confidence in him & his decisions.

Mar 2015

•

Verified SHC Patient

Dr. Alizadeh is extremely bright and very compassionate & thoughtful. I am in such excellent health because of his care, a very wonderful individual.

Feb 2015

•

Verified SHC Patient

I believe Dr. Alizadeh and team have saved my life.

Jan 2015

•

Verified SHC Patient

Very organized.

Dec 2014

•

Verified SHC Patient

I was somewhat disappointed not to be able to make my next annual appointment.

Dec 2014

•

Verified SHC Patient

This visit I saw more of the physician at the outset: I do not like the visits where I spend most of my time with the nurse practitioner & every thing is filtered thru her to the physician who I see very briefly.

Oct 2014

•

Verified SHC Patient

Dr. Arash Ash Alizadeh is an excellent doctor. He saved my life from non-Hodgkin lymphoma.

Sep 2014

•

Verified SHC Patient

Dr. Ash is very professional and competent. We really like him. Thanks Dr. Ash for being so kind!

Aug 2014

•

Verified SHC Patient

Excellent physician with lots of compassion and concern about my health.

Dec 2013

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Ash A. Alizadeh, MD/PhD

Medical oncologist, Lymphoma specialist, Cancer geneticist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Lymphoma Program Palo Alto, CA

Lymphoma Program

Lymphoma Program in Palo Alto Palo Alto, CA

Lymphoma Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(87 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Ash A. Alizadeh, MD/PhD

Medical oncologist, Lymphoma specialist, Cancer geneticist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Lymphoma Program Palo Alto, CA

Lymphoma Program

Lymphoma Program in Palo Alto Palo Alto, CA

Lymphoma Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(87 reviews)

Referring Physicians

PHYSICIAN HELPLINE